GlassScriptPhysician profile
Oganes Paronian
NPI 1528048899
$1,852.00
in general payments reported to CMS, 2019-2025
28 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $39.79 · 2021: $317 · 2022: $174 · 2023: $370 · 2024: $389 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $249.18 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Lilly USA, LLC | $235.13 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Shield Therapeutics INC | $181.17 | 2023-2025 | Accrufer |
| Abbvie INC. | $146.86 | 2021-2025 | |
| Novo Nordisk INC | $133.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $127.23 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $115.14 | 2021-2022 | |
| Amgen INC. | $96.82 | 2022-2025 | Prolia, Evenity, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $96.72 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $47.36 | 2022-2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.16 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $38.58 | 2021 | |
| Hologic Sales and Service, LLC | $34.84 | 2024 | Thinprep 2000 Processor, Affirm Prone Biopsy System |
| Merck Sharp & Dohme LLC | $32.97 | 2019-2024 | M-M-R II, Vaxelis, Gardasil |
| Pfizer INC. | $28.92 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $27.53 | 2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $26.28 | 2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $24.48 | 2022 | |
| Alkermes, INC. | $24.04 | 2019 | |
| Sanofi Pasteur INC. | $18.87 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $18.64 | 2025 | Zoryve |
| Cranial Technologies, INC | $18.09 | 2024 | Doc Band |
| Mannkind Corporation | $16.87 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.33 | 2022 | |
| Astellas Pharma US INC | $14.90 | 2019 | |
| Amarin Pharma, INC. | $14.52 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.41 | 2024 | Xifaxan, Trulance |
| Scilex Pharmaceuticals INC. | $14.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oganes Paronian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.